CE
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Neurocognition and NMDAR co-agonists pathways in individuals with treatment resistant first-episode psychosis : a 3-year follow-up longitudinal study | Molecular psychiatry | 2024 | 45 | 34 | |||
| Infant exposure to Fluvoxamine through placenta and human milk : a case series - A contribution from the ConcePTION project | Frontiers in psychiatry | 2023 | 73 | 41 | |||
| Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortium | Schizophrenia research | 2022 | 39 | 43 | |||
| Body Composition Assessment by Dual-Energy X-Ray Absorptiometry: A Useful Tool for the Diagnosis of Lipedema | Obesity facts | 2022 | 184 | 367 | |||
| Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia | JAMA psychiatry | 2022 | 28 | 52 | |||
| Case Report: Opioid Use Disorder Associated With Low/Moderate Dose of Loperamide in an Intellectual Disability Patient With CYP3A and P-Glycoprotein Reduced Activity | Frontiers in psychiatry | 2022 | 99 | 97 | |||
| Effect of Quetiapine, from Low to High Dose, on Weight and Metabolic Traits: Results from a Prospective Cohort Study | Pharmacopsychiatry | 2021 | 198 | 2,786 | |||
| Bioavailability of Vortioxetine After a Roux-en-Y Gastric Bypass | Obesity Surgery | 2020 | 262 | 1 | |||
| A population pharmacokinetic model for escitalopram and its major metabolite in depressive patients during the perinatal period: Prediction of infant drug exposure through breast milk | British Journal of Clinical Pharmacology | 2020 | 437 | 2 | |||
| Genetic and clinic predictors of new onset diabetes mellitus after transplantation | The Pharmacogenomics Journal | 2019 | 364 | 0 | |||
| Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients | American Journal of Transplantation | 2019 | 445 | 0 | |||
| Associations of Urinary Caffeine and Caffeine Metabolites With Arterial Stiffness in a Large Population-Based Study | Mayo Clinic Proceedings | 2018 | 476 | 1 | |||
| Association Between Plasma Caffeine and Other Methylxanthines and Metabolic Parameters in a Psychiatric Population Treated With Psychotropic Drugs Inducing Metabolic Disturbances | Frontiers in Psychiatry | 2018 | 454 | 197 | |||
| N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis | Schizophrenia bulletin | 2018 | 93 | 19 | |||
| CRTC2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation | Pharmacogenomics journal | 2017 | 703 | 0 | |||
| Association of genetic risk scores with body mass index in Swiss psychiatric cohorts | Pharmacogenetics and genomics | 2016 | 565 | 0 | |||
| Bon usage des antidépresseurs ISRS durant la grossesse – le défi de l'évaluation de la balance bénéfice-risque | Revue médicale suisse | 2016 | 688 | 5 | |||
| Association of PCK1 with Body Mass Index and Other Metabolic Features in Patients With Psychotropic Treatments | Journal of clinical psychopharmacology | 2015 | 598 | 1 | |||
| Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments | Pharmacogenetics and genomics | 2015 | 659 | 0 | |||
| Associations of ambulatory blood pressure with urinary caffeine and caffeine metabolite excretions | Hypertension | 2015 | 591 | 1 | |||
| Influence of MCHR2 and MCHR2-AS1 Genetic Polymorphisms on Body Mass Index in Psychiatric Patients and In Population-Based Subjects with Present or Past Atypical Depression | PloS one | 2015 | 611 | 207 | |||
| Blood pressure in relation to coffee and caffeine consumption | Current hypertension reports | 2014 | 592 | 1 | |||
| Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance | British journal of clinical pharmacology | 2014 | 588 | 0 | |||
| Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women | Antiviral therapy | 2013 | 592 | 0 | |||
| Influence of CRTC1 polymorphisms on body mass index and fat mass in psychiatric patients and the general adult population | JAMA psychiatry | 2013 | 680 | 0 | |||
| Caffeine intake and CYP1A2 variants associated with high caffeine intake protect non-smokers from hypertension | Human molecular genetics | 2012 | 848 | 2 | |||
| Quantification of 4 antidepressants and a metabolite by LC-MS for therapeutic drug monitoring | Journal of chromatography. B | 2011 | 757 | 2 | |||
| The permeability P-glycoprotein: a focus on enantioselectivity and brain distribution | Expert opinion on drug metabolism & toxicology | 2010 | 619 | 0 | |||
| The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone | British journal of pharmacology | 2010 | 869 | 2 | |||
| Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety | British journal of pharmacology | 2010 | 643 | 1 | |||
| Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study | European journal of clinical pharmacology | 2009 | 714 | 275 | |||
| Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MS | Journal of pharmaceutical and biomedical analysis | 2009 | 700 | 0 | |||
| Validation and long-term evaluation of a modified on-line chiral analytical method for therapeutic drug monitoring of (R,S)-methadone in clinical samples | Journal of chromatography. B | 2009 | 628 | 0 | |||
| Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals | Clinical pharmacology and therapeutics | 2009 | 669 | 0 | |||
| Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizer: Evidence of a safer cardiac profile of (R)-methadone | Pharmacopsychiatry | 2008 | 671 | 0 | |||
| CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response | Therapeutic drug monitoring | 2008 | 783 | 0 | |||
| Over- and underreporting of recent drug use in subjects entering an inpatient detoxification unit | European journal of medical research | 2008 | 481 | 0 | |||
| Follow-up of the metabolic syndrome induced by atypical antipsychotics: recommendations and pharmacogenetics perspectives | Revue médicale suisse | 2008 | 768 | 442 |
